Researchers at the University of Kentucky Markey Cancer Center have found that a drug commonly used to treat patients with malaria may be helpful in treating those with metastatic cancer.
Carried out in the lab of Dr. Vivek M. Rangnekar, the Alfred Cohen-endowed chair of Oncology Research at the UK Markey Cancer Center, Rangekar, along with co-authors, Drs. Ravshan Burikhanov and Nikhil Hebbar, found that the drug, chloroquine, prompted the secretion of Par-4, a tumor suppressor protein, in both mouse models and cancer patients taking part in a clinical trial. Par-4 is essential for tumor cell death and is key in preventing tumor metastasis.
Read more about this new cutting-edge research at Medicalxpress.com.